Symbiome

Symbiome operates within the health and wellness sector, providing direct-to-consumer gut microbiome analysis. The company, established in 2010, targets individuals seeking to improve their overall wellbeing through a deeper understanding of their intestinal health. It functions on a B2C business model, generating revenue by selling at-home test kits.

The service entails the customer collecting a stool sample, which is then sent for laboratory analysis. Symbiome provides the client with a detailed report, accessible on digital devices, that outlines the composition of their gut flora. This analysis identifies and quantifies the various microorganisms present. Based on these results, the company offers personalized lifestyle recommendations to its customers. The scientific connection between gut microbiota and conditions like insomnia provides a significant market context for the company's services.

For its core analysis, Symbiome has established a strategic partnership with Carbiotix, a publicly-listed, ISO-certified biotechnology company based in Sweden. This collaboration ensures that the laboratory analysis is conducted using advanced methods, including next-generation DNA sequencing (NGS), to deliver precise and reliable results. This partnership is a key operational component, allowing Symbiome to focus on the customer-facing aspects of its service while leveraging a specialized, high-quality laboratory for the scientific analysis.

Keywords: gut microbiome testing, intestinal flora analysis, direct-to-consumer health, B2C wellness, microbiome diagnostics, gut-brain axis, personalized nutrition, home health test, DNA sequencing, Carbiotix, gut health report, wellness technology, digestive health, microbial analysis, health-tech, personalized wellness, stool sample analysis, gut dysbiosis, next-generation sequencing, lifestyle recommendations